Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: efficacy and toxicity in the DELINEATE trial.
To report a planned analysis of the efficacy and toxicity of dose escalation to the intraprostatic dominant nodule identified on multiparametric MRI (mp-MRI) using standard and hypofractionated external beam radiotherapy. XXX is a single centre prospective phase 2 multi-cohort study including standard (Cohort A: 74Gy/37F) and moderately hypofractionated (Cohort B: 60Gy/20F) prostate image-guided IMRT in patients with NCCN intermediate and high-risk disease. Patients received an integrated boost of 82Gy (Cohort A) and 67Gy (Cohort B) to mp-MRI-visible lesions. 55 patients were treated within Cohort A and 158 patients treated in Cohort B; the first 50 sequentially treated patients in Cohort B were included in this planned analysis. The primary endpoint was late RTOG rectal toxicity at 1 year. Secondary endpoints included acute and late toxicity measured with clinician and patient reported outcomes at other timepoints as well as biochemical relapse (BCR) free survival for Cohort A. Median follow up for Cohort A was 74.5 months and 52.0 months for Cohort B. In Cohort A and B, there were 27% and 40% of patients respectively classified with NCCN high risk disease. The cumulative 1-year incidence of Radiation Therapy Oncology Group (RTOG) grade 2 or worse rectal and urinary toxicity was 3.6% and 0% in Cohort A and 8% and 10% in Cohort B respectively. There was no reported late grade 3 rectal toxicity in either cohort. At a median follow up of 74.5 months (Cohort A) and 52 months (Cohort B) four patients, all from cohort A, had BCR. Delivery of a simultaneous integrated boost to intraprostatic dominant nodules is feasible in prostate radiotherapy using standard and moderately hypofractionated regimens, with rectal and genitourinary toxicity comparable to contemporary series without an intra-prostatic boost.